Prothena Corporation PLC Stock Price, News & Analysis (NASDAQ:PRTA)

$46.03 0.18 (0.39 %)
(As of 11/24/2017 04:00 PM ET)
Previous Close$45.85
Today's Range$45.40 - $46.41
52-Week Range$44.43 - $70.00
Volume89,560 shs
Average Volume296,284 shs
Market Capitalization$1.76 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.55

About Prothena Corporation PLC (NASDAQ:PRTA)

Prothena Corporation PLC logoProthena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). The Company has generated monoclonal antibodies that selectively bind to amyloidogenic (diseased) forms of the Transthyretin (TTR)-mediated amyloidosis (ATTR) protein. The Company's pipeline also includes late discovery-stage programs for which the Company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion.

Receive PRTA News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PRTA
CUSIPN/A
Phone353-1236-2500

Debt

Debt-to-Equity RatioN/A
Current Ratio11.95%
Quick Ratio11.95%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.05 million
Price / Sales1,685.57
Cash FlowN/A
Price / CashN/A
Book Value$11.61 per share
Price / Book3.96

Profitability

Trailing EPS($4.23)
Net Income$-160,100,000.00
Net Margins-562.19%
Return on Equity-34.40%
Return on Assets-28.61%

Miscellaneous

Employees96
Outstanding Shares38,450,000

Frequently Asked Questions for Prothena Corporation PLC (NASDAQ:PRTA)

What is Prothena Corporation PLC's stock symbol?

Prothena Corporation PLC trades on the NASDAQ under the ticker symbol "PRTA."

How were Prothena Corporation PLC's earnings last quarter?

Prothena Corporation PLC (NASDAQ:PRTA) released its earnings results on Tuesday, November, 7th. The biotechnology company reported ($1.37) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($1.41) by $0.04. The biotechnology company earned $0.19 million during the quarter, compared to analyst estimates of $0.28 million. Prothena Corporation PLC had a negative net margin of 562.19% and a negative return on equity of 34.40%. The business's revenue was down 33.6% on a year-over-year basis. During the same quarter last year, the business earned ($1.26) EPS. View Prothena Corporation PLC's Earnings History.

When will Prothena Corporation PLC make its next earnings announcement?

Prothena Corporation PLC is scheduled to release their next quarterly earnings announcement on Monday, February, 12th 2018. View Earnings Estimates for Prothena Corporation PLC.

Where is Prothena Corporation PLC's stock going? Where will Prothena Corporation PLC's stock price be in 2017?

12 equities research analysts have issued twelve-month price objectives for Prothena Corporation PLC's stock. Their predictions range from $55.00 to $100.00. On average, they anticipate Prothena Corporation PLC's stock price to reach $77.73 in the next twelve months. View Analyst Ratings for Prothena Corporation PLC.

What are Wall Street analysts saying about Prothena Corporation PLC stock?

Here are some recent quotes from research analysts about Prothena Corporation PLC stock:

  • 1. Cantor Fitzgerald analysts commented, "Gotta be in it to win it. The logic behind impeding cell trafficking as a means treating T cell-mediated autoimmune disorders has been established with Tysabri in relapsing forms of MS, so the merits of pursuing non-CNS indications makes abundant sense to us." (9/28/2017)
  • 2. According to Zacks Investment Research, "The narrower-than-expected loss in the second quarter was encouraging. Prothena’s efforts on developing its pipeline are encouraging. The company's license agreement with Roche for the development and commercialization of selected antibodies targeting alpha-synuclein is a big positive. The collaboration not only boosts Prothena’s pipeline development but also provides it with funds in the form of research reimbursement and milestone payments. Prothena recently earned a $30 million of milestone payment from Roche. The company’s shares have outperformed the industry in the past one year. We expect investor focus to remain on further updates from its late-stage candidate, NEOD001. However, Prothena is highly dependent on its collaboration partners for the development of its candidates. The company itself does not have enough resources to independently conduct studies on its candidates." (8/11/2017)
  • 3. Instinet analysts commented, "We are initiating on Prothena Corporation (PRTA) with a Buy rating and an $87 target price. We recommend owning PRTA shares ahead of Phase 2b PRONTO trial readout expected in early 2018 for lead asset NEOD001 in AL amyloidosis (a >$1.5bn peak sales opportunity). We view the pullback from 2016 highs and recent lows as an opportunity to accumulate the shares ahead of PRONTO data. Positive results from PRONTO based on change in NT-proBNP, a biomarker that NEOD001 substantially moved, yielding 53% responder rate in an early Phase 1/2b, are likely to support a conditional approval in the EU by 2019. In addition, we expect biomarker data from the PRX003 Phase 1b study to define mechanistically the breadth opportunity for MCAM/Th17-cell targeting in autoimmune disease, a potential multibillion dollar opportunity that, in our view, will raise the floor on PRTA's valuation. PRX002 could become a strong driver of PRTA's valuation in out years; however, given few near-term catalysts, it is unlikely to be a driver for PRTA shares in the next 12 months." (3/1/2017)

Who are some of Prothena Corporation PLC's key competitors?

Who are Prothena Corporation PLC's key executives?

Prothena Corporation PLC's management team includes the folowing people:

  • Lars G. Ekman M.D., Ph.D., Independent Chairman of the Board (Age 67)
  • Gene G. Kinney Ph.D., President, Chief Executive Officer, Director (Age 48)
  • Tran B. Nguyen, Chief Financial Officer (Age 43)
  • Karin L. Walker CPA, Chief Accounting Officer, Controller (Age 53)
  • Wagner Zago, Chief Scientific Officer
  • Arthur W. Homan, Chief Legal Officer (Age 57)
  • Carol D. Karp, Chief Regulatory Officer (Age 64)
  • Martin Koller M.D., Chief Medical Officer (Age 66)
  • Tara Nickerson Ph.D., Chief Business Officer (Age 44)
  • K. Anders O. Harfstrand M.D., Ph.D., Director (Age 60)

Who owns Prothena Corporation PLC stock?

Prothena Corporation PLC's stock is owned by many different of retail and institutional investors. Top institutional investors include Woodford Investment Management Ltd (29.65%), Westfield Capital Management Co. LP (1.62%), Jennison Associates LLC (1.07%), Pinnacle Associates Ltd. (0.94%), Oak Ridge Investments LLC (0.75%) and Hood River Capital Management LLC (0.52%). Company insiders that own Prothena Corporation PLC stock include Arthur W Homan, Christopher S Henney, Dennis J Selkoe, Gene G Kinney, Karin L Walker, Lars Ekman, Tara Nickerson and Tran Nguyen. View Institutional Ownership Trends for Prothena Corporation PLC.

Who sold Prothena Corporation PLC stock? Who is selling Prothena Corporation PLC stock?

Prothena Corporation PLC's stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Oak Ridge Investments LLC, Westfield Capital Management Co. LP, Woodford Investment Management Ltd, Nationwide Fund Advisors, Pinnacle Associates Ltd., California State Teachers Retirement System and Platinum Investment Management Ltd.. Company insiders that have sold Prothena Corporation PLC company stock in the last year include Arthur W Homan, Christopher S Henney, Dennis J Selkoe, Gene G Kinney, Karin L Walker and Tara Nickerson. View Insider Buying and Selling for Prothena Corporation PLC.

Who bought Prothena Corporation PLC stock? Who is buying Prothena Corporation PLC stock?

Prothena Corporation PLC's stock was bought by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Sectoral Asset Management Inc, Westpac Banking Corp, Sphera Funds Management LTD., Schwab Charles Investment Management Inc., Parametrica Management Ltd, Hood River Capital Management LLC and Birchview Capital LP. View Insider Buying and Selling for Prothena Corporation PLC.

How do I buy Prothena Corporation PLC stock?

Shares of Prothena Corporation PLC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Prothena Corporation PLC's stock price today?

One share of Prothena Corporation PLC stock can currently be purchased for approximately $46.03.

How big of a company is Prothena Corporation PLC?

Prothena Corporation PLC has a market capitalization of $1.76 billion and generates $1.05 million in revenue each year. The biotechnology company earns $-160,100,000.00 in net income (profit) each year or ($4.23) on an earnings per share basis. Prothena Corporation PLC employs 96 workers across the globe.

How can I contact Prothena Corporation PLC?

Prothena Corporation PLC's mailing address is ADELPHI PLAZA UPPER GEORGE`S STREET, DUN LAOGHAIRE L2, A96 T927. The biotechnology company can be reached via phone at 353-1236-2500 or via email at [email protected]


MarketBeat Community Rating for Prothena Corporation PLC (PRTA)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  284 (Vote Outperform)
Underperform Votes:  152 (Vote Underperform)
Total Votes:  436
MarketBeat's community ratings are surveys of what our community members think about Prothena Corporation PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Prothena Corporation PLC (NASDAQ:PRTA)

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.832.892.942.71
Ratings Breakdown: 1 Sell Rating(s)
1 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $75.27$76.73$77.93$76.67
Price Target Upside: 44.94% upside32.50% upside35.09% upside47.78% upside

Consensus Price Target History for Prothena Corporation PLC (NASDAQ:PRTA)

Price Target History for Prothena Corporation PLC (NASDAQ:PRTA)

Analysts' Ratings History for Prothena Corporation PLC (NASDAQ:PRTA)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/20/2017WedbushDowngradeOutperform -> Neutral$75.00 -> $55.00N/AView Rating Details
11/9/2017Oppenheimer Holdings, Inc.Reiterated RatingBuy$70.00N/AView Rating Details
10/23/2017Deutsche Bank AGSet Price TargetBuy$73.00N/AView Rating Details
10/2/2017Jefferies Group LLCReiterated RatingBuy$100.00LowView Rating Details
10/2/2017SunTrust Banks, Inc.Reiterated RatingBuy$75.00LowView Rating Details
9/29/2017Royal Bank Of CanadaReiterated RatingBuyHighView Rating Details
9/29/2017BTIG ResearchLower Price TargetBuy -> Buy$80.00 -> $77.00HighView Rating Details
9/28/2017Cantor FitzgeraldReiterated RatingBuy$79.00MediumView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$83.00HighView Rating Details
5/16/2017Piper Jaffray CompaniesReiterated RatingBuyMediumView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$87.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
9/27/2016Credit Suisse GroupReiterated RatingBuy$65.00N/AView Rating Details
8/4/2016Barclays PLCBoost Price TargetOverweight$60.00 -> $70.00N/AView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for Prothena Corporation PLC (NASDAQ:PRTA)

Earnings by Quarter for Prothena Corporation PLC (NASDAQ:PRTA)

Earnings History by Quarter for Prothena Corporation PLC (NASDAQ PRTA)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/12/2018($1.47)N/AView Earnings Details
11/7/2017Q3($1.41)($1.37)$0.28 million$0.19 millionViewN/AView Earnings Details
8/8/20176/30/2017($0.89)($0.46)$16.08 million$26.81 millionViewN/AView Earnings Details
5/9/20173/31/2017($1.32)($0.99)$0.26 million$0.26 millionViewN/AView Earnings Details
2/14/2017Q416($1.12)($1.41)$5.35 million$0.20 millionViewListenView Earnings Details
11/1/2016Q3($1.22)($1.26)$0.49 million$0.29 millionViewN/AView Earnings Details
8/2/2016Q2($0.91)($1.18)$0.39 million$0.33 millionViewN/AView Earnings Details
5/3/2016Q116($0.77)($0.81)$0.27 million$0.27 millionViewN/AView Earnings Details
2/18/2016Q215($0.81)($0.76)$0.39 million$0.31 millionViewListenView Earnings Details
11/2/2015($0.66)($0.73)$0.28 million$0.43 millionViewN/AView Earnings Details
8/4/2015Q2($0.56)($0.59)$0.60 million$0.28 millionViewN/AView Earnings Details
5/5/2015($0.59)($0.55)$1.95 million$0.59 millionViewN/AView Earnings Details
3/5/2015Q414($0.66)($0.48)$1.20 million$2.00 millionViewN/AView Earnings Details
11/3/2014Q314($0.60)($0.48)$1.13 million$1.50 millionViewN/AView Earnings Details
8/4/2014Q214$0.06$15.17 million$15.12 millionViewN/AView Earnings Details
5/5/2014$0.81$0.78$30.17 million$32.23 millionViewN/AView Earnings Details
3/6/2014Q113($0.52)ViewN/AView Earnings Details
3/28/2013Q412($0.82)$0.13 million$0.58 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Prothena Corporation PLC (NASDAQ:PRTA)
2017 EPS Consensus Estimate: ($4.96)
2018 EPS Consensus Estimate: ($5.63)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($1.42)($1.28)($1.36)
Q2 20174($1.20)($0.50)($0.87)
Q3 20174($1.54)($1.21)($1.36)
Q4 20174($1.45)($1.29)($1.38)
Q1 20182($1.49)($1.45)($1.47)
Q2 20182($1.60)($1.35)($1.48)
Q3 20182($1.55)($1.16)($1.36)
Q4 20182($1.61)($1.05)($1.33)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Prothena Corporation PLC (NASDAQ:PRTA)

No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Prothena Corporation PLC (NASDAQ PRTA)

Insider Ownership Percentage: 3.10%
Insider Trades by Quarter for Prothena Corporation PLC (NASDAQ:PRTA)
Institutional Ownership by Quarter for Prothena Corporation PLC (NASDAQ:PRTA)

Insider Trades by Quarter for Prothena Corporation PLC (NASDAQ PRTA)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/2/2017Dennis J SelkoeDirectorSell3,500$64.17$224,595.00View SEC Filing  
9/28/2017Christopher S HenneyDirectorSell900$70.00$63,000.00View SEC Filing  
9/28/2017Gene G KinneyInsiderSell2,800$70.00$196,000.00View SEC Filing  
9/27/2017Tara NickersonInsiderSell4,724$69.05$326,192.20View SEC Filing  
9/25/2017Tara NickersonInsiderSell17,500$63.60$1,113,000.00View SEC Filing  
7/17/2017Karin L WalkerInsiderSell5,000$64.89$324,450.00View SEC Filing  
7/7/2017Dennis J SelkoeDirectorSell3,500$58.11$203,385.00View SEC Filing  
4/17/2017Karin L WalkerInsiderSell5,000$52.25$261,250.00View SEC Filing  
4/3/2017Dennis J SelkoeDirectorSell3,500$55.86$195,510.00View SEC Filing  
3/9/2017Tran NguyenCFOBuy1,000$51.32$51,320.00View SEC Filing  
1/4/2017Arthur W HomanInsiderSell3,125$52.25$163,281.25View SEC Filing  
11/28/2016Dennis J SelkoeDirectorSell5,000$62.42$312,100.00View SEC Filing  
11/9/2016Gene G KinneyInsiderSell8,548$55.32$472,875.36View SEC Filing  
10/21/2016Gene G KinneyInsiderSell20,619$55.10$1,136,106.90View SEC Filing  
10/13/2016Karin L WalkerInsiderSell5,000$54.23$271,150.00View SEC Filing  
9/19/2016Karin L WalkerInsiderSell12,000$61.10$733,200.00View SEC Filing  
9/1/2016Arthur W HomanInsiderSell3,125$52.16$163,000.00View SEC Filing  
7/20/2016Arthur W HomanInsiderSell9,375$52.14$488,812.50View SEC Filing  
5/24/2016Dennis J SelkoeDirectorSell5,000$45.00$225,000.00View SEC Filing  
4/13/2016Karin L WalkerInsiderSell4,000$45.11$180,440.00View SEC Filing  
4/4/2016Dennis J SelkoeDirectorSell5,000$45.00$225,000.00View SEC Filing  
1/13/2016Karin L. WalkerinsiderSell4,000$50.96$203,840.00View SEC Filing  
12/9/2015Tara NickersoninsiderSell10,000$66.17$661,700.00View SEC Filing  
12/9/2015Tran NguyenCFOSell30,000$66.17$1,985,100.00View SEC Filing  
12/1/2015Dennis J. SelkoeDirectorSell3,125$68.74$214,812.50View SEC Filing  
11/27/2015Christopher S. HenneyDirectorSell5,000$75.00$375,000.00View SEC Filing  
11/25/2015Lars EkmanDirectorSell30,000$73.35$2,200,500.00View SEC Filing  
11/13/2015Martin KollerinsiderSell30,000$65.03$1,950,900.00View SEC Filing  
11/2/2015Arthur W. HomaninsiderSell3,125$52.14$162,937.50View SEC Filing  
10/29/2015Christopher S. HenneyDirectorSell5,000$55.00$275,000.00View SEC Filing  
9/9/2015Tara NickersoninsiderSell10,000$56.06$560,600.00View SEC Filing  
9/2/2015Martin KollerinsiderSell30,000$55.56$1,666,800.00View SEC Filing  
9/1/2015Dennis J. SelkoeDirectorSell3,125$55.45$173,281.25View SEC Filing  
8/20/2015Dale B. SchenkCEOSell30,000$56.65$1,699,500.00View SEC Filing  
8/12/2015Karin L WalkerInsiderSell7,000$62.06$434,420.00View SEC Filing  
6/9/2015Tara NickersonInsiderSell12,000$44.41$532,920.00View SEC Filing  
3/20/2015Tara NickersonInsiderSell13,000$39.99$519,870.00View SEC Filing  
3/9/2015Dennis J SelkoeDirectorSell3,125$25.56$79,875.00View SEC Filing  
8/12/2014Karin L WalkerInsiderSell2,500$20.74$51,850.00View SEC Filing  
8/7/2014Arthur W HomanInsiderBuy2,000$19.12$38,240.00View SEC Filing  
6/6/2014Karin L WalkerInsiderSell8,000$21.58$172,640.00View SEC Filing  
5/12/2014Dale SchenkCEOBuy8,000$20.79$166,320.00View SEC Filing  
5/12/2014Tara NickersonInsiderBuy1,656$21.00$34,776.00View SEC Filing  
5/9/2014Gene KinneyInsiderBuy2,500$19.54$48,850.00View SEC Filing  
5/9/2014Tran NguyenCFOBuy2,200$19.61$43,142.00View SEC Filing  
2/3/2014Co Plc Perrigomajor shareholderSell3,182,253$24.96$79,429,034.88View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Prothena Corporation PLC (NASDAQ PRTA)

Source:
DateHeadline
Prothena Corporation plc: Prothena to Participate in the Evercore ISI Biopharma Catalyst/Deep Dive ConferenceProthena Corporation plc: Prothena to Participate in the Evercore ISI Biopharma Catalyst/Deep Dive Conference
www.finanznachrichten.de - November 23 at 7:48 AM
Prothena to Participate in the Evercore ISI Biopharma Catalyst/Deep Dive ConferenceProthena to Participate in the Evercore ISI Biopharma Catalyst/Deep Dive Conference
finance.yahoo.com - November 23 at 7:48 AM
Wedbush Weighs in on Prothena Corporation PLCs FY2017 Earnings (PRTA)Wedbush Weighs in on Prothena Corporation PLC's FY2017 Earnings (PRTA)
www.americanbankingnews.com - November 22 at 6:20 AM
Prothena Corporation PLC (PRTA) Lowered to "Neutral" at WedbushProthena Corporation PLC (PRTA) Lowered to "Neutral" at Wedbush
www.americanbankingnews.com - November 20 at 8:52 PM
Prothena is Now Oversold (PRTA)Prothena is Now Oversold (PRTA)
www.nasdaq.com - November 18 at 11:03 AM
Prothena Highlights Breadth of Novel Pipeline at R&D DayProthena Highlights Breadth of Novel Pipeline at R&D Day
finance.yahoo.com - November 18 at 11:03 AM
Prothena Corporation PLC Expected to Post FY2017 Earnings of ($4.23) Per Share (PRTA)Prothena Corporation PLC Expected to Post FY2017 Earnings of ($4.23) Per Share (PRTA)
www.americanbankingnews.com - November 13 at 2:34 AM
Jefferies Group Brokers Boost Earnings Estimates for Prothena Corporation PLC (PRTA)Jefferies Group Brokers Boost Earnings Estimates for Prothena Corporation PLC (PRTA)
www.americanbankingnews.com - November 10 at 1:54 PM
Prothena Corporation PLCs (PRTA) Buy Rating Reaffirmed at Oppenheimer Holdings, Inc.Prothena Corporation PLC's (PRTA) Buy Rating Reaffirmed at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - November 9 at 1:54 PM
Prothena Reports Third Quarter 2017 Financial Results and Provides R&D UpdateProthena Reports Third Quarter 2017 Financial Results and Provides R&D Update
finance.yahoo.com - November 9 at 11:57 AM
Prothena reports 3Q lossProthena reports 3Q loss
finance.yahoo.com - November 9 at 11:57 AM
Woodford-backed Prothena targeted by short seller KerrisdaleWoodford-backed Prothena targeted by short seller Kerrisdale
finance.yahoo.com - November 9 at 11:57 AM
$300,000.00 in Sales Expected for Prothena Corporation PLC (PRTA) This Quarter$300,000.00 in Sales Expected for Prothena Corporation PLC (PRTA) This Quarter
www.americanbankingnews.com - November 9 at 10:30 AM
Prothena Corporation PLC (PRTA) Issues  Earnings Results, Beats Estimates By $0.03 EPSProthena Corporation PLC (PRTA) Issues Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - November 7 at 6:34 PM
-$1.41 EPS Expected for Prothena Corporation PLC (PRTA) This Quarter-$1.41 EPS Expected for Prothena Corporation PLC (PRTA) This Quarter
www.americanbankingnews.com - November 7 at 9:42 AM
Prothena Corporation PLC (PRTA) Receives Consensus Recommendation of "Buy" from AnalystsProthena Corporation PLC (PRTA) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 6 at 8:28 PM
Prothena Corp. Plc breached its 50 day moving average in a Bullish Manner : PRTA-US : November 3, 2017Prothena Corp. Plc breached its 50 day moving average in a Bullish Manner : PRTA-US : November 3, 2017
finance.yahoo.com - November 4 at 9:05 AM
Prothena to Participate in the Credit Suisse 26th Annual Healthcare ConferenceProthena to Participate in the Credit Suisse 26th Annual Healthcare Conference
finance.yahoo.com - November 2 at 7:56 AM
Prothena Corporation PLC (PRTA) to Release Earnings on TuesdayProthena Corporation PLC (PRTA) to Release Earnings on Tuesday
www.americanbankingnews.com - November 1 at 10:49 AM
Whats in the Cards for Prothena (PRTA) in Q3 Earnings?What's in the Cards for Prothena (PRTA) in Q3 Earnings?
finance.yahoo.com - November 1 at 7:42 AM
What's in the Cards for Prothena (PRTA) in Q3 Earnings?What's in the Cards for Prothena (PRTA) in Q3 Earnings?
finance.yahoo.com - November 1 at 7:42 AM
Prothena to Report Third Quarter 2017 Financial Results on November 7Prothena to Report Third Quarter 2017 Financial Results on November 7
finance.yahoo.com - November 1 at 7:42 AM
Financial Comparison: Prothena Corporation PLC (PRTA) vs. Its CompetitorsFinancial Comparison: Prothena Corporation PLC (PRTA) vs. Its Competitors
www.americanbankingnews.com - October 27 at 11:26 PM
Deutsche Bank AG Reiterates $73.00 Price Target for Prothena Corporation PLC (PRTA)Deutsche Bank AG Reiterates $73.00 Price Target for Prothena Corporation PLC (PRTA)
www.americanbankingnews.com - October 23 at 11:20 PM
Prothena Corporation PLC (PRTA) to Release Earnings on MondayProthena Corporation PLC (PRTA) to Release Earnings on Monday
www.americanbankingnews.com - October 23 at 11:18 AM
 Analysts Anticipate Prothena Corporation PLC (PRTA) Will Announce Quarterly Sales of $440,000.00 Analysts Anticipate Prothena Corporation PLC (PRTA) Will Announce Quarterly Sales of $440,000.00
www.americanbankingnews.com - October 20 at 5:14 AM
 Analysts Anticipate Prothena Corporation PLC (PRTA) Will Post Earnings of -$1.38 Per Share Analysts Anticipate Prothena Corporation PLC (PRTA) Will Post Earnings of -$1.38 Per Share
www.americanbankingnews.com - October 18 at 4:22 PM
Commit To Buy Prothena Corp At $40, Earn 10.2% Annualized Using OptionsCommit To Buy Prothena Corp At $40, Earn 10.2% Annualized Using Options
www.nasdaq.com - October 17 at 4:15 PM
Prothena Corp. Plc – Value Analysis (NASDAQ:PRTA) : October 16, 2017Prothena Corp. Plc – Value Analysis (NASDAQ:PRTA) : October 16, 2017
finance.yahoo.com - October 17 at 6:28 AM
Prothena Corp. Plc – Value Analysis (NASDAQ:PRTA) : October 16, 2017Prothena Corp. Plc – Value Analysis (NASDAQ:PRTA) : October 16, 2017
finance.yahoo.com - October 17 at 6:28 AM
Prothena Corp. Plc breached its 50 day moving average in a Bearish Manner : PRTA-US : October 13, 2017Prothena Corp. Plc breached its 50 day moving average in a Bearish Manner : PRTA-US : October 13, 2017
finance.yahoo.com - October 14 at 6:56 AM
Prothena Corporation PLC (PRTA) Given Consensus Rating of "Buy" by BrokeragesProthena Corporation PLC (PRTA) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 12 at 6:56 PM
Short Interest Moves 24.5% Lower For PRTAShort Interest Moves 24.5% Lower For PRTA
www.thestreet.com - October 12 at 8:30 AM
Prothena Corporation PLC (PRTA) Rating Lowered to Sell at ValuEngineProthena Corporation PLC (PRTA) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - October 7 at 10:34 PM
Reviewing Prothena Corporation PLC (PRTA) and Versartis (VSAR)Reviewing Prothena Corporation PLC (PRTA) and Versartis (VSAR)
www.americanbankingnews.com - October 7 at 6:28 PM
Prothena Co. PLC (PRTA) Director Dennis J. Selkoe Sells 3,500 SharesProthena Co. PLC (PRTA) Director Dennis J. Selkoe Sells 3,500 Shares
www.americanbankingnews.com - October 4 at 8:02 PM
FY2017 EPS Estimates for Prothena Co. PLC Lifted by Analyst (PRTA)FY2017 EPS Estimates for Prothena Co. PLC Lifted by Analyst (PRTA)
www.americanbankingnews.com - October 4 at 8:42 AM
Head to Head Contrast: PTC Therapeutics (PTCT) & Prothena Corporation PLC (PRTA)Head to Head Contrast: PTC Therapeutics (PTCT) & Prothena Corporation PLC (PRTA)
www.americanbankingnews.com - October 3 at 10:22 PM
Prothenas Psoriasis Candidate Disappoints in Phase I Study - NasdaqProthena's Psoriasis Candidate Disappoints in Phase I Study - Nasdaq
www.nasdaq.com - October 3 at 11:06 AM
Prothena's Psoriasis Candidate Disappoints in Phase I StudyProthena's Psoriasis Candidate Disappoints in Phase I Study
finance.yahoo.com - October 3 at 11:06 AM
Prothena Corporation PLC (PRTA) Stock Rating Reaffirmed by Deutsche Bank AGProthena Corporation PLC (PRTA) Stock Rating Reaffirmed by Deutsche Bank AG
www.americanbankingnews.com - October 2 at 3:14 PM
Prothena Corporation PLC (PRTA) Rating Reiterated by Jefferies Group LLCProthena Corporation PLC (PRTA) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - October 2 at 1:20 PM
Prothena Corporation PLC (PRTA) Earns Buy Rating from SunTrust Banks, Inc.Prothena Corporation PLC (PRTA) Earns Buy Rating from SunTrust Banks, Inc.
www.americanbankingnews.com - October 2 at 1:20 PM
-$1.38 EPS Expected for Prothena Corporation PLC (PRTA) This Quarter-$1.38 EPS Expected for Prothena Corporation PLC (PRTA) This Quarter
www.americanbankingnews.com - September 29 at 10:08 PM
Christopher S. Henney Sells 900 Shares of Prothena Corporation PLC (PRTA) StockChristopher S. Henney Sells 900 Shares of Prothena Corporation PLC (PRTA) Stock
www.americanbankingnews.com - September 29 at 8:52 PM
Prothena Corporation PLC (PRTA) Insider Sells $196,000.00 in StockProthena Corporation PLC (PRTA) Insider Sells $196,000.00 in Stock
www.americanbankingnews.com - September 29 at 8:04 PM
Prothena Corporation PLC (PRTA) Insider Tara Nickerson Sells 4,724 SharesProthena Corporation PLC (PRTA) Insider Tara Nickerson Sells 4,724 Shares
www.americanbankingnews.com - September 29 at 8:02 PM
Pre-Open Movers 09/29: (ZGNX) (VERI) (ROKU) Higher; (GWPH) (PRTA) (GLYC) Lower (more...) - StreetInsider.comPre-Open Movers 09/29: (ZGNX) (VERI) (ROKU) Higher; (GWPH) (PRTA) (GLYC) Lower (more...) - StreetInsider.com
www.streetinsider.com - September 29 at 6:18 PM
Prothena Corp. (PRTA) Says Results from Phase 1b Study Doesnt Support Moving PRX003 into Mid-Stage Development - StreetInsider.comProthena Corp. (PRTA) Says Results from Phase 1b Study Doesn't Support Moving PRX003 into Mid-Stage Development - StreetInsider.com
www.streetinsider.com - September 29 at 6:18 PM
Prothena Corporation PLCs (PRTA) Buy Rating Reaffirmed at Royal Bank Of CanadaProthena Corporation PLC's (PRTA) Buy Rating Reaffirmed at Royal Bank Of Canada
www.americanbankingnews.com - September 29 at 6:00 PM

Social Media

Financials

Chart

Prothena Corporation PLC (NASDAQ PRTA) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.